CMS Proposes Formal Rules to Strengthen Medicare Drug Price Negotiations

The Centers for Medicare and Medicaid Services (CMS) has introduced a proposal to formalize the Medicare Drug Price Negotiation Program, shifting it from its current status as a set of nonbinding guidance documents to a codified federal rule. By establishing these requirements as official regulations, the agency aims to create a more robust legal framework that is significantly more difficult for pharmaceutical companies to challenge in court. These changes, if finalized, would govern the negotiation process for drugs selected for the 2029 cycle and beyond.

A central component of this proposal is the closure of a strategic loophole that allows manufacturers to bypass price negotiations. Currently, drugmakers may attempt to avoid federal oversight by slightly modifying a product’s inactive ingredients or changing its delivery method, effectively rebranding it as a "new" drug to reset its eligibility status. The new CMS rule would prevent this by allowing the agency to treat different products with the same active ingredient as a single entity for negotiation purposes, provided they are owned by the same license holder.

This shift represents a significant escalation in the federal government's effort to control rising healthcare costs under the Inflation Reduction Act. By codifying these processes, CMS is signaling a long-term commitment to the negotiation program, reducing the ambiguity that currently exists under guidance-based enforcement. As the agency enters a 60-day public comment period ending August 17, 2026, the proposal sets the stage for a more rigid regulatory environment that will likely face intense scrutiny from the pharmaceutical industry, which has historically resisted federal price-setting mechanisms.